Renal improvement in myeloma with plasma exchange [5]

New England Journal of Medicine

Volumn 365, Issue 11, 2011, Pages 1061-1062

  Hutchison, Colin ^a   Bridoux, Frank ^b   Fermand, Jean Paul ^c  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^b POITIERS UNIVERSITY HOSPITAL   (France)

^c SAINT LOUIS HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

BORTEZOMIB; ANTINEOPLASTIC AGENT; BORONIC ACID DERIVATIVE; PYRAZINE DERIVATIVE; DEXAMETHASONE; IMMUNOGLOBULIN LIGHT CHAIN;

CANCER SURVIVAL; CAST NEPHROPATHY; HEMODIALYSIS; HUMAN; KIDNEY DISEASE; LETTER; MYELOMA; PLASMAPHERESIS; PRIORITY JOURNAL; TREATMENT RESPONSE; ACUTE KIDNEY FAILURE; MULTIMODALITY CANCER THERAPY; MULTIPLE MYELOMA; NOTE; APHERESIS; DIALYSIS; BLOOD;

ACUTE KIDNEY INJURY; ANTINEOPLASTIC AGENTS; BORONIC ACIDS; COMBINED MODALITY THERAPY; HUMANS; MULTIPLE MYELOMA; PLASMA EXCHANGE; PYRAZINES; IMMUNOGLOBULIN LIGHT CHAINS;

EID: 80052848345     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMc1108282     Document Type: Letter

References (4)

1. Burnette BL, Leung N, Rajkumar SV. Renal improvement in myeloma with bortezomib plus plasma exchange. N Engl J Med 2011;364:2365-6.
2. Hutchison CA, Cockwell P, Stringer S, et al. Early reduction of serum-free light chains associates with renal recovery in myeloma kidney. J Am Soc Nephrol 2011;22:1129-36.
3. Hutchison CA, Cockwell P, Reid S, et al. Efficient removal of immunoglobulin free light chains by hemodialysis for multiple myeloma: in vitro and in vivo studies. J Am Soc Nephrol 2007;18:886-95. (Pubitemid 46434505)
4. Clark WF, Stewart AK, Rock GA, et al. Plasma exchange when myeloma presents as acute renal failure: a randomized, controlled trial. Ann Intern Med 2005;143:777-84. [Erratum, Ann Intern Med 2007;146:471.]